source
- Summit Therapeutics and Akeso celebrate third China approval for ivonescimab as new data show waning survival benefitSummit Therapeutics and its partner Akeso received a third approval in China for ivonescimab, a PD-1/VEGF bispecific antibody, for first-line treatment of advanced squamous non-small cell lung canc…
- AstraZeneca halts late-stage lung cancer trial of volrustomig after disappointing interim resultsAstraZeneca said it is ending its Phase 3 eVOLVE-Lung02 trial that evaluated the bispecific antibody volrustomig combined with chemotherapy as a first-line option for metastatic non-small cell lung…BioSpace · 2h agoNegative readoutNegative